What is the recommended management for a patient with severe immune thrombocytopenia (platelet count <30 × 10⁹/L) who is actively bleeding or at high risk of bleeding?

Management of Severe ITP

For severe ITP (platelet count <30 × 10⁹/L) with active bleeding or high bleeding risk, initiate combination therapy with corticosteroids plus intravenous immunoglobulin (IVIg), and add platelet transfusions if life-threatening bleeding is present. 1

Initial Assessment and Risk Stratification

When evaluating severe ITP, immediately assess:

• Bleeding severity: Distinguish between minor mucocutaneous bleeding (petechiae, purpura) versus major bleeding (intracranial hemorrhage, hemodynamic instability, critical site bleeding)
• Warning signs: Oral purpura and gross hematuria often precede major bleeds and warrant aggressive intervention 2
• Platelet count: Severe bleeding typically occurs only when platelets fall <10 × 10⁹/L, though risk exists throughout the <30 × 10⁹/L range 3

First-Line Treatment Algorithm

For Active Bleeding or High-Risk Patients

Immediate combination therapy is essential:

1. Corticosteroids (choose one):

   • High-dose dexamethasone OR
   • Intravenous methylprednisolone
   • Longer courses (≤6 weeks) are preferred over shorter courses 1

2. IVIg: 1 g/kg as one-time dose when rapid platelet increase is required 1

   • Use with corticosteroids for faster response
   • May repeat if necessary
   • Alternative: Anti-D immunoglobulin in appropriate Rh-positive, non-splenectomized patients

3. Platelet transfusions: Reserved for life-threatening bleeding (intracranial hemorrhage, hemodynamic instability) 4, 2

   • Despite theoretical concerns about antibody formation, transfuse to achieve hemostasis in critical situations
   • Combine with IVIg and high-dose steroids

Important Caveat

The 2011 ASH guidelines suggest treatment for platelet counts <30 × 10⁹/L (grade 2C), but treatment decisions should be driven by bleeding symptoms, not platelet count alone 1. Asymptomatic patients with counts 20-30 × 10⁹/L may be managed as outpatients with close follow-up 5.

Hospitalization Criteria

Admit patients with:

• Platelet count <20 × 10⁹/L with any mucosal bleeding
• Major bleeding at any platelet count
• Refractory to initial treatment
• Significant comorbidities increasing bleeding risk
• Social concerns or inability to ensure rapid follow-up 5

Patients with counts ≥20 × 10⁹/L who are asymptomatic or have only minor mucocutaneous bleeding may be managed outpatient with hematology follow-up within 24-72 hours 5.

Second-Line Options for Refractory Cases

If initial therapy fails after ≥3 months or patient is corticosteroid-dependent:

The 2026 ASH guidelines (most recent) recommend:

• Thrombopoietin receptor agonists (TPO-RAs) as strong recommendation for corticosteroid-refractory disease 6
• Either eltrombopag (oral) or romiplostim (subcutaneous injection) 5
• TPO-RAs are preferred over rituximab for second-line therapy 5, 6

Alternative second-line options:

• Rituximab: Conditional recommendation, particularly if TPO-RAs contraindicated 5, 6
• Splenectomy: Should be delayed ≥12 months if possible, as up to one-third achieve satisfactory response without it 1, 4

Emergency Management of Life-Threatening Bleeding

For catastrophic bleeding (intracranial hemorrhage, severe gastrointestinal bleeding):

1. Platelet transfusions - transfuse aggressively despite ITP
2. IVIg - 1 g/kg immediately
3. High-dose corticosteroids - IV methylprednisolone
4. Consider emergency splenectomy if bleeding uncontrollable with medical therapy 7

This requires a median of 3 treatments simultaneously 2. Mortality in major ITP bleeds reaches 10%, with 31% developing recurrent bleeds 2.

Common Pitfalls to Avoid

• Don't delay treatment in patients with oral purpura or hematuria even if platelet count >20 × 10⁹/L - these predict progression to major bleeding 2
• Don't withhold platelet transfusions in life-threatening bleeding due to theoretical concerns - survival takes precedence 4, 2
• Don't use prolonged corticosteroid courses (>6 weeks) - strong recommendation against this due to toxicity without added benefit 5
• Don't rush to splenectomy - delay at least 12 months unless severe refractory bleeding, as many patients achieve remission 1, 4

Monitoring During Acute Phase

• Platelet counts every 24-48 hours until stable response
• Daily assessment for new bleeding symptoms
• Monitor for corticosteroid side effects (hyperglycemia, psychiatric symptoms, hypertension)
• Ensure hematology follow-up within 24-72 hours of diagnosis or relapse 5

The goal is achieving platelet count >20-30 × 10⁹/L to prevent severe bleeding, not normalization of counts 4, 3.